Global X Guru Index ETF

Global X Guru Index ETF (GURU) tracks the Solactive Guru Index. The index holds the single largest disclosed stock position of each of a select group of hedge funds, taken from their quarterly Form 13F filings. Each stock gets an equal weight, so mid-sized biotech companies sit alongside larger firms. Its 0.75% expense ratio is above the 0.53% average of similar funds, and its yield is close to zero.

• Over the year to Oct 27, 2026, GURU returned +6.9%, 7th of 7 among similar funds.
• Its 5-year annualized return was +5.9% and its 10-year +11.6%.
• In the 2020 COVID crash it fell 37% and regained its old high 4.8 months after the low.
• Its worst full calendar year was 2022 (-28.0%); its best was 2013 (+47.3%).
• The deepest fall in its price history was 38.5% (Sep 2, 2021 to Oct 14, 2022), recovered by Nov 6, 2024.

As of Jul 31, 2026, the fund held 87 securities; the ten largest made up 16.19% of assets.

• Over the three months to Jul 31, 2026, investors added a net $10.5M (creations minus redemptions, per the N-PORT report).
• Monthly total returns reported for that quarter: -3.98%, +3.56%, +5.42%.

GURU follows the Solactive Guru Index. The index comes from Solactive AG, a company that is not affiliated with Global X. It starts with Form 13F filings, which are quarterly reports that large investment managers file with the SEC listing their US-listed stock holdings. To qualify, a hedge fund must report at least $500 million in holdings. It also can't trade its stocks too often, and it must have a concentrated top holding. The index then takes each qualifying fund's single largest position.

Those stocks are screened for liquidity (how easily they trade), given equal weights and rebalanced every quarter on the 13F filing schedule. The index had 78 stocks as of December 31, 2025, and the fund held 87 positions as of July 31, 2026. Because of equal weighting, the largest holding, Corcept Therapeutics, was only about 2.3% of assets. The portfolio turnover rate of 86.33% shows how often holdings change.

Global X generally uses replication, which means buying every index stock in about the same proportions as the index. One built-in limit matters: 13F filings arrive up to 45 days after each quarter ends. A hedge fund may have already sold a stock by the time the index adds it, and a filing may show only part of a manager's holdings. The fund may also lend out securities worth up to one-third of its total assets.

• GURU charges 0.75% a year, versus an average of 0.53% for the similar funds below (5th of 7, cheapest first).
• Using the prospectus's standard example, $10,000 invested would cost about $77 in the first year and $930 over 10 years (assuming a 5% annual return).

GURU is an equal-weighted, biotech-heavy bet on hedge funds' top stock picks that has fallen harder than the broad market, so it fits better as a small add-on than as a core holding.

GURU's one-year beta was 1.1, meaning it tended to move a bit more than the market. It fell 37% in the 2020 COVID crash but recovered in about 4.8 months. The 2022 decline was harder. The fund lost 27.74% that year, its worst calendar year. Its deepest drop, 38.5% from September 2021 to October 2022, took until November 2024 to recover, about 25 months. Anyone who had to sell shares during that stretch would have locked in losses. The fund launched in 2012, so it has no record from 2008. It offers almost no income: the trailing 12-month yield was 0.08% as of October 27, 2026, paid once a year. In the SEC's standard example, costs on $10,000 come to $77 after one year and $930 after 10 years. Past results don't predict the future, and a plan should look at the whole portfolio, not one fund.

Matched by closest holdings overlap from the latest N-PORT reports (no similar fund shares 20% or more of its holdings).